Oakworth Capital’s DexCom DXCM Stock Holding History

Oakworth Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500	Closed	-$58.1K	–	635
2023 Q1	$58.1K	Buy	+500	New	+$56K	0.01%	283

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Oakworth Capital's DXCM Position: Q2 2023 in Review

Oakworth Capital sold out of DexCom (DXCM) in Q2 2023, closing a stake of 500 shares — an estimated $58.1K sold.

Oakworth Capital first reported a position in DXCM in Q1 2023 and held it in 1 quarter. The position peaked at $58.1K in Q1 2023. 954 funds tracked by Wall St. Rank hold DXCM as of Q2 2023.

Oakworth Capital reported no remaining DexCom position as of Q2 2023 after selling out during the quarter.
Oakworth Capital sold 500 DexCom shares in Q2 2023, an estimated $58.1K.
Oakworth Capital first reported a position in DexCom in Q1 2023 and held it in 1 quarter.
Oakworth Capital's DexCom position peaked at $58.1K in Q1 2023.
954 funds tracked by Wall St. Rank held DexCom as of Q2 2023.

Based on Oakworth Capital's 13F filing for Q2 2023, filed 28 Jul 2023.